Search 

Meet Chromatin Bioscience at the UK Pavilion, booth 38.
By mining the genome using our bioinformatics platform we discover and re-purpose natural gene regulatory elements, creating customised gene expression systems to:

Creating highly selective and controllable promoters and gene expression cassettes for novel gene and cell therapy systems

Improving the efficiency of b iologics production by increasing protein yields in upstream manufacturing processes

Harnessing synthetic biology by making promoters for the wide array of chassis organisms used in Industrial Biotech

Creating switches and gene circuits to be employed in any metabolic engineering application

Designing tissue-selective plant synthetic promoters active across  different crop species for Agricultural Biotech applications

Using plant genomics to facilitate the design of environmentally-regulated and pathogen-responsive promoters

Meet Mesenbio at the UK Pavilion, booth 38.
By advancing beyond symptom management, we aim to not only halt disease progression but also reverse its impact, offering patients a path to improved functionality and long-term relief. Our innovative platform provides a foundation for developing scalable, standardized therapies that could reshape rheumatoid arthritis treatment for the future.

Meet Onyx Scientific at the UK Pavilion, booth 38.
Onyx Scientific is a small molecule CDMO specialising in process R&D, non-GMP scale up and GMP manufacture for clinical trials and commercial. Good chemistry is at the core of everything we do. From our facilities in the UK and US, our teams of chemists will guide your small molecule API through development and manufacturing from the moment a lead molecule is identified, taking it into Phase I studies and right through to commercial manufacture.

Meet RoslinCT at the UK Pavilion, booth 38.
RoslinCT, as one of the first in the world to produce clinical-grade human pluripotent stem cells, has a strong focus on science and innovation. In collaboration with Vertex Pharmaceuticals, RoslinCT developed, from early process development through commercialization, the First CRISPR-Edited Cell Therapy Product, exa-cel for the treatment of sickle cell disease and transfusion-dependent beta thalassemia.